Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study
You may not be if
Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH
Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization
Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)
Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection
Has a history of nephrotic syndrome
Has severe renal insufficiency
Has received certain therapies in the prohibited timeframe as specified in the protocol
Has active or chronic hepatobiliary or hepatic disease
Has poorly controlled Type 1 or Type 2 diabetes
Clareo Health | A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
